Skip to content
Head to head

Enliven Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ELVN · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

ELVN +113.8%VRTX +18.7%
Enliven Therapeutics edges it on the scoreable measures. Enliven Therapeutics has the highest Quant Rating (98); Enliven Therapeutics has done best over the past year (+119%).
ELVNVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price46.53515.02
Change today+0.26%-1.08%
1-year return+118.8%+22.0%
Market cap$3.42B$130.58B
52-week range14.79 – 62.32412.27 – 568.67
Valuation
P/E (TTM)-27.5333.14
P/E percentile, own 5-yr range19th99th
P/B3.906.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.8315.32
Net profit (TTM)$-134.68M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-66.41M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership118.0%96.8%
Insider activity (12mo)15 buy / 35 sell28 buy / 22 sell
Short interest (% of float)14.0%1.9%
Analyst consensus100% buy (10)95% buy / 5% hold (21)
Analyst price target$75 (+61%)$624 (+21%)
StockVane view
StockVane Quant RatingC (98)C (68)
Company
Employees606,400
Founded20191989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.